Epidemiology and screening for renal cancer. by Rossi, Sabrina et al.
Vol.:(0123456789) 
World Journal of Urology 
https://doi.org/10.1007/s00345-018-2286-7
INVITED REVIEW
Epidemiology and screening for renal cancer
Sabrina H. Rossi1  · Tobias Klatte2  · Juliet Usher‑Smith3  · Grant D. Stewart1 
Received: 6 February 2018 / Accepted: 28 March 2018 
© The Author(s) 2018
Abstract
Purpose The widespread use of abdominal imaging has affected the epidemiology of renal cell carcinoma (RCC). Despite 
this, over 25% of individuals with RCC have evidence of metastases at presentation. Screening for RCC has the potential to 
downstage the disease.
Methods We performed a literature review on the epidemiology of RCC and evidence base regarding screening. Further-
more, contemporary RCC epidemiology data was obtained for the United Kingdom and trends in age-standardised rates of 
incidence and mortality were analysed by annual percentage change statistics and joinpoint regression.
Results The incidence of RCC in the UK increased by 3.1% annually from 1993 through 2014. Urinary dipstick is an inad-
equate screening tool due to low sensitivity and specificity. It is unlikely that CT would be recommended for population 
screening due to cost, radiation dose and increased potential for other incidental findings. Screening ultrasound has a sen-
sitivity and specificity of 82–83% and 98–99%, respectively; however, accuracy is dependent on tumour size. No clinically 
validated urinary nor serum biomarkers have been identified. Major barriers to population screening include the relatively 
low prevalence of the disease, the potential for false positives and over-diagnosis of slow-growing RCCs. Individual patient 
risk-stratification based on a combination of risk factors may improve screening efficiency and minimise harms by identify-
ing a group at high risk of RCC.
Conclusion The incidence of RCC is increasing. The optimal screening modality and target population remain to be eluci-
dated. An analysis of the benefits and harms of screening for patients and society is warranted.
Keywords Renal cell carcinoma · Screening · Ultrasound · Early detection · Review
Introduction
Renal cell carcinoma (RCC) is the 9th most common cancer 
in men and 14th most common cancer in women worldwide 
[1]. RCC is the most lethal urological malignancy, yet risk 
factors for the disease have not been completely elucidated 
[2, 3]. Screening for RCC remains an attractive prospect; 
however, the ideal screening modality and screening strategy 
have yet to be determined. This review summarises the epi-
demiology of RCC and current evidence base on screening, 
including potential screening modalities, target populations 
and risk prediction models to aid early detection.
Methods
We systematically searched the Medline database up to 
November 2017 to identify studies on screening for RCC. 
In addition, a separate search was performed to identify 
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studies reporting risk prediction models for the develop-
ment of RCC in asymptomatic individuals. The full details 
of the keywords and subject headings used are available in 
Table S1 (supporting information). The search was limited 
to English language and human studies. The reference lists 
of relevant articles were reviewed manually. Studies were 
included if they reported risk of RCC in adults representa-
tive of the general population. We excluded studies reporting 
data on symptomatic individuals and those pooling renal and 
urothelial cancers as the outcome.
Furthermore, to include the most contemporary data 
on the epidemiology of RCC in the United Kingdom, we 
obtained RCC incidence and mortality data for 1993–2014 
by querying the online database of Cancer Research UK 
(http://www.cance rrese archu k.org/healt h-profe ssion al/cance 
r-stati stics /stati stics -by-cance r-type/kidne y-cance r, access: 
3 January 2018). Age-standardised incidence and mortal-
ity rates were extracted per 100,000 population. Trends in 
overall RCC incidence and according to age and gender 
were analysed with joinpoint regression models (Joinpoint 
4.1; IMS, Calverton, United States). Up to five joinpoints 
were allowed for trends. Trends during time periods were 
described as annual percentage change (APC).
Results
Renal cancer epidemiology
The incidence of RCC is increasing worldwide and is posi-
tively correlated with gross domestic product per capita 
[4]. Incidence is highest in developed countries, with rates 
15-fold higher in North America, Northern and Eastern 
Europe compared to Africa and South-East Asia [1]. Estab-
lished risk factors for RCC include increasing age, smok-
ing, obesity, and hypertension (Table 1) [5–7]. The rising 
incidence of RCC in rapidly developing countries may be 
partially attributable to increases in these established risk 
factors, as well as increased detection of incidental malig-
nancy identified with the widespread use of imaging modali-
ties for other abdominal complaints [1, 8, 9]. The propor-
tion of all RCC diagnosed incidentally is now over 50% 
Table 1  Risk factors for renal cell carcinoma (RCC)
NSAIDs non-steroidal anti-inflammatory drugs
Risk factor Comment
Established risk factors
 Male gender Positive association [1, 86]
 Age Positive association [1]
 Obesity Positive association with a dose response [5, 86]
 Smoking Positive association with a dose response [86]
 Hypertension Positive association with a dose response. Effect of hypertensive medication on renal cancer risk 
remains unclear [86, 87]
 Renal disease Increased risk of renal cancer in acquired cystic kidney disease, end-stage renal disease, renal 
transplant
 Alcohol Moderate alcohol intake has a protective effect relative to abstinence. There is no additional benefit 
for higher consumption [88–90]
 Family history Affected first-degree relative confers a risk of renal cancer.
A number of inherited rare genetic conditions also predispose to renal cancer, including von 
Hippel–Lindau, hereditary papillary renal carcinoma, Birt–Hogg–Dubé syndrome, hereditary 
leiomyomatosis renal cell carcinoma, succinate dehydrogenase renal cell carcinoma, and tuberous 
sclerosis. [91]
Risk factors that are less well characterised
 Physical activity High/strenuous physical activity is protective [92]
 Diabetes Positive association [93]
 Occupational exposure Trichloroethylene is considered a carcinogenic agent with sufficient evidence for the development 
of renal cancer according to the International Agency for Research on Cancer [94, 95]. Arse-
nic and inorganic arsenic compounds, cadmium and cadmium compounds, perfluorooctanoic 
acid printing processes and welding fumes have limited evidence according to the International 
Agency for Research on Cancer [95]
 Gamma radiation and X radiation Carcinogenic agent with sufficient evidence in humans according to the International Agency for 
Research on Cancer [95]
 Analgesic use Meta-analyses suggest acetaminophen is associated with a significant risk of developing kidney 
cancer. Conflicting results are available regarding non-aspirin NSAIDs. Aspirin did not demon-
strate a significant association [96, 97]
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[10, 11]. It is estimated that 43% of Medicare beneficiaries 
aged 65–85 years in the USA undergo either a CT chest or 
CT abdomen over a 5-year period [12]. This “unsystematic 
screening” has resulted in a size and stage migration towards 
smaller RCC, with an associated improvement in survival in 
many developed countries [10].
Mortality rates are stable or decreasing in the majority of 
Western countries, however, the decline is more pronounced 
in Western compared to Eastern Europe and North compared 
to South America [4]. RCC mortality continues to rise in 
Eastern Europe, however [4]. Renal cancer contributes to 
a greater average number of years of life lost (a measure 
of cancer burden dependent on patient age at death and the 
number of deaths at each age) than both colorectal and pros-
tate cancer [13, 14].
UK figures on RCC incidence and mortality are shown 
in Fig. 1. Overall, the age-standardised RCC incidence rate 
increased by 3.1% per year (95% CI 2.8–3.4%) from 1993 
through 2014. The overall APC was 2.2% between 1993 
and 2003 and 3.9% between 2003 and 2014. Both males 
and females demonstrated a comparable increase (Fig. 1a). 
The increase in RCC incidence rates was greatest in older 
Fig. 1  Age-standardised renal 
cell carcinoma incidence rates 
according to gender (a) and age 
group (b) in the UK population 
between 1993 and 2014. Inci-
dence rates rose continuously 
(average annual percentage 
change 3.1%), especially in the 
elderly. In contrast, mortality 
rates (c) increased only to a 
minor extent (average annual 
percentage change 1.1%), indi-
cating improvements in relative 
survival
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age groups (Fig. 1b). In fact, the average APC was 2.9% 
(95% CI 2.2–3.5%) in individuals aged 25–49 years, 3.4% 
for individuals aged 70–79 year and 4.6% in patients aged 
> 80 years. In contrast to incidence, mortality rates increased 
only to a minor extent (average annual percentage change 
1.1% [95% CI 0.9–1.2%], Fig. 1c), suggesting improvements 
in relative survival.
Rationale for screening
Early diagnosis and screening for RCC has been identified 
as a key research priority within this disease [15]. Despite 
this, relatively little research has been published regarding 
screening for RCC over the last decade. RCC fulfils many 
of the Wilson and Jungner criteria for suitability for screen-
ing, however, a number of key uncertainties require further 
research (Table 2) [14]. Overall survival from RCC is poor, 
with a 47% 5-year age-standardized relative survival rate 
in the United Kingdom. Over a quarter of individuals diag-
nosed with RCC have evidence of metastases at presenta-
tion and 5-year age-standardized relative survival rate for 
stage IV disease is 6% compared to 84% in stage I [16]. 
Incidentally detected tumours are generally smaller in size 
and are associated with improved survival relative to symp-
tomatic tumours, independent of tumour grade and stage 
[17, 18]. A screening programme may improve survival 
outcomes through earlier detection and treatment of RCC 
at a curable stage. RCC is generally considered a “surgi-
cal disease”; management is operative in all but the most 
advanced cases, where systemic therapies may prolong life 
but not provide a cure [19, 20]. As such, early diagnosis 
is paramount to optimizing survival [19]. Early detection 
of smaller tumours may allow increasing use of minimally 
invasive techniques such as robotic or laparoscopic partial 
nephrectomy and tumour ablation, reducing rates of open 
surgery with associated high morbidity and hospital stay 
[21–24]. Modern systemic therapies used in the treatment 
of metastatic RCC, such as sunitinib, pazopanib, axitinib 
and nivolumab, are highly expensive and the median cost of 
anticancer drugs is rising, as is patient life expectancy, and 
therefore, duration of treatment [25, 26]. It has been postu-
lated that screening for RCC may be a cost-effective strategy 
Table 2  Wilson and Jungner criteria applied to screening for renal cell carcinoma (RCC) [14]
AAA abdominal aortic aneurysm, RCC renal cell carcinoma, SRM small renal mass
Criteria for screening Application to RCC screening
The condition sought should be an important health problem Renal cancer is the 7th most common cancer in Europe [98]
There should be an accepted treatment for patients with recognised 
disease
Detection of smaller tumours may preferentially allow minimally inva-
sive techniques reducing rates of open surgery, and therefore, associ-
ated morbidity and length of hospital stay
Facilities for diagnosis and treatment should be available In a health service with a finite budget, important considerations must 
be made regarding the cost of investigations and management of 
patients found to have benign SRMs on screening
There should be a recognisable latent or early symptomatic stage The sojourn time of RCC is between 3.7 and 5.8 years, suggesting that 
most RCCs have a detectable preclinical period [44]
There should be a suitable test of examination Focused renal ultrasound thus far represents the only validated screening 
tool, with high sensitivity (82–83.3%) and specificity (98–99.3%) [56, 
57]. Accurate and inexpensive, non-invasive methods of renal cancer 
detection, using blood or urine as the substrate, remain a research 
priority
The test should be acceptable to the population Ultrasound is non-invasive and well tolerated by the general population. 
AAA screening is performed with ultrasound and attendance rates are 
84–85%, with similar rates expected for RCC. [48, 49]
The natural history of the condition, including development from 
latent to declared disease, should be adequately understood
Reliable clinical predictors of a tumour’s growth rate and aggressiveness 
are not available
Advances have been made in understanding the natural history of small 
renal masses and the
European Active SurveillancE of Renal cancer (EASE study) aims to 
clarify this further [99]
There should be an agreed policy on whom to treat as patients. Clear European Association of Urology guidelines have been published 
regarding the management of RCC [7]
The cost of case finding (including diagnosis and treatment of patients 
diagnosed) should be economically balanced in relation to possible 
expenditure on medical care as a whole
A cost-effectiveness analysis is warranted and constitutes a key research 
priority highlighted in this analysis
Case finding should be a continuing process and not a “once and for 
all” project
A cost-effectiveness analysis may elucidate the optimal screening fre-
quency, be it one off screening such as AAA, or recurrent screening
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through downstaging the disease, reducing the prevalence of 
metastatic tumours and associated expenditure relating to 
systemic therapies. However, the ideal screening modality 
is yet to be determined.
Urine dipstick as a screening modality
The incidence of visible and non-visible haematuria is 35% 
in patients with known RCC, compared to 94% in patients 
with urothelial carcinoma of the bladder or ureter [27]. 
Kang et al. reported results of urinary dipstick performed in 
a screening paradigm in 56,632 asymptomatic healthy indi-
viduals aged ≥ 20 years undergoing a “health check-up.” The 
prevalence of non-visible haematuria at initial urinalysis was 
6.2% (3517/56,632), however, in this young, and therefore, 
low-risk population, only three RCC (prevalence 0.005%) 
and three bladder cancers were subsequently detected [28]. 
A feasibility study of population screening utilising home 
urinary dipstick followed by urinary biomarkers testing in 
men aged 50–75 years has also been performed. 1747 men 
were screened but although 23% tested positive for non-
visible haematuria, requiring biomarker testing and subse-
quent imaging, only four bladder and one renal malignancies 
were detected. One bladder cancer and one renal cancer were 
missed [29]. Microscopic haematuria is a relatively com-
mon and very non-specific finding; therefore, a substantial 
proportion of individuals screened by dipstick will require 
further investigation, to detect only a very small number of 
RCCs. Several other studies have been performed evaluat-
ing urine dipstick in screening for renal and bladder cancer, 
however, the low diagnostic yield and high number of false 
positives and false negatives preclude this as a screening tool 
for RCC [29–31].
Biomarkers as a screening modality
Several serum and urine biomarkers have been proposed 
as potential screening tools. Soluble urinary proteins are 
an attractive candidate due to their relative stability and 
straightforward method of detection via antibody or ligand-
based techniques [32]. Perhaps the most promising urinary 
biomarkers are aquaporin 1 (AQP1) and perilipin 2 (PLIN2). 
These biomarkers can differentiate RCC from healthy con-
trols, benign renal masses and non-renal urological cancers 
[33, 34]. Recently, Morrissey et al. evaluated AQP1 and 
PLIN2 levels prospectively in a screening paradigm in 720 
asymptomatic individuals undergoing abdominal CT for a 
medical reason not related to RCC, 18 patients with his-
tologically proven RCC and 80 self-selected healthy con-
trols. The sensitivity of both biomarkers was 85–92% and 
the specificity 87–100%; with an area under the ROC of 
0.95 and 0.91 for AQP1 and PLIN2, respectively. External 
validation of these urinary biomarkers in a larger prospective 
cohort is paramount. However, AQP1 and PLIN2 are mark-
ers of clear cell or papillary, but not chromophobe RCC, 
raising the potential for false-negative results in a screen-
ing population. AQP1 levels also correlated with tumour 
size but not grade, raising the issue of potential detection 
of indolent renal masses that would never become clinically 
significant [35, 36]. In addition, evaluation of PLIN2 using 
Western Blot limits applicability as a screening tool as this 
is a time consuming, expensive and technically demanding 
method [37].
Other plasma and urinary biomarkers have also been 
evaluated. A composite three marker assay [based on nico-
tinamide N-methyltransferase (NNMT), L-plastin (LCP1) 
and non-metastatic cells 1 protein (NM23A)] was developed 
and had 90% sensitivity, 95.7% specificity and diagnostic 
AUC 0.932 for RCC versus healthy controls. However, the 
assay has limited ability to distinguish RCC from benign 
renal tumours [38]. Han et al. showed urinary KIM1 is also 
significantly higher in patients with RCC than controls, how-
ever, its use as a diagnostic marker is limited by low specific-
ity [39, 40]. Frantzi et al. demonstrated that though a single 
urinary peptide with diagnostic value was not identified, a 
model based on 87 peptides has reported 80% sensitivity 
and 87% specificity [41]. Accurate and inexpensive, non-
invasive methods of renal cancer detection, using blood or 
urine as the substrate, remain a research priority. Evaluation 
of cell-free DNA is one such avenue currently under evalu-
ation [42].
Computed tomography as a screening modality
Although non-contrast CT has not been proposed as a dedi-
cated screening tool for RCC, the value of screening abdom-
inal CT for the simultaneous detection of aortic aneurysms 
and a variety of solid abdominal organ malignancies has 
been investigated [43]. Ishikawa et al. screened 4543 healthy 
individuals aged ≥ 40 years, however, the prevalence of solid 
organ malignancy was only 0.1% and thus they concluded 
that screening low-risk individuals was unlikely to be cost-
effective [43]. Fenton et al. estimated the pooled prevalence 
of renal cancer detected in middle-aged American individu-
als undergoing a variety of screening CT modalities (includ-
ing whole body CT, CT screening for lung cancer, colorectal 
cancer and coronary artery disease) as 0.21%, which is sub-
stantially higher [44]. Renal lesions are the most common 
extracolonic finding noted on CT colonography performed 
during screening for colorectal cancer, suggesting CT colo-
nography may enable early detection of incidental RCC [45]. 
However, it is widely recognised that CT colonography leads 
to considerable over-diagnosis of a variety of indeterminate 
visceral lesions. Extracolonic findings are noted in 40–70% 
of screening CT colonography. Of these, 5–35% require fur-
ther imaging or follow-up, but only 3% require treatment, 
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with significant burden on patients and resources [46]. A 
health economic analysis has demonstrated that whole body 
CT is not a cost-effective screening intervention due to the 
high financial burden associated with follow-up for false-
positive- and incidental findings [47]. In view of this, it is 
unlikely non-contrast abdominal CT would ever be recom-
mended for population screening for RCC [46].
Ultrasound as a screening modality
Ultrasound has arisen as a potential screening tool for RCC 
as it is a widely utilised, established, inexpensive, non-inva-
sive technique of identifying renal lesions without exposure 
to radiation. National abdominal aortic aneurysm (AAA) 
screening programmes in men over the age of 65 years are 
established in the United Kingdom and Sweden and have 
demonstrated that an ultrasound-based screening programme 
can be delivered by trained technicians in a primary care set-
ting [48, 49]. These screening programmes are ideal vehicles 
to explore the possibility of screening for RCC due to the 
similarities in risk factors and mode of detection between 
RCC and AAA [50].
Ultrasound is less sensitive and specific compared to CT 
for the detection of RCC, with ultrasound detection rates 
dependent on renal lesion size. Ultrasound enables the detec-
tion of 85–100% tumours > 3 cm in size, but only 67–82% 
of tumours 2–3 cm in size [51–53]. Therefore, ultrasound 
screening for RCC has the potential to lead to false-negative 
results in masses < 3 cm in size. Complete diagnostic visu-
alisation of kidneys by ultrasound occurs in 97.4% of cases, 
comparing favourably with 98.8% visualisation rates of the 
aorta in AAA screening [54, 55]. Mizuma et al. and Filipas 
et al. report an excellent sensitivity (82–83.3%) and speci-
ficity (98–99.3%) of ultrasound for detecting RCC in the 
general population as part of a screening intervention [56, 
57]. The potential for false-negative results was not based on 
CT which is generally considered gold standard, but rather 
repeat ultrasound at a 1-year interval and follow-up via a 
registry and health records. This may artificially inflate the 
reported accuracy of ultrasound.
Several observational studies have been published on 
screening for RCC using ultrasound, however, none have 
been randomized in design, and all were published more 
than a decade ago [50, 56–61] (Table 3). Mihara et  al. 
screened 219,640 asymptomatic Japanese individuals 
selected from the general population (age range 29–70 years) 
over a 13-year period [60]. RCC was detected in 192 cases: 
37.8% of detected tumours were < 25 mm in size and only 
19.2% of tumours were > 51 mm. No patients had lymph 
node or distant metastases. Screen-detected RCC was 
associated with excellent survival outcomes, with 97.4% 
cumulative survival rates at 5 years and 94.6% at 10 years. 
Tosaka et al. retrospectively report the results of 41,364 
abdominal ultrasounds performed at their institution, includ-
ing 20,897 asymptomatic individuals undergoing a routine 
“health check-up” and 20,467 patients undergoing investi-
gations for a non-urological complaint [62]. 5-year survival 
in this asymptomatic group of individuals diagnosed with 
RCC was significantly better than that observed in symp-
tomatic patients diagnosed with RCC at the same institu-
tion (94.7 vs 60.9%, p < 0.01). Filipas et al. and Malaeb 
et al. performed focused renal ultrasound screening of the 
general population in a prospective manner. In the former, 
screening was performed in 9959 asymptomatic individu-
als > 40 years recruited from the general population [57]. 
Eleven individuals were diagnosed with RCC. There was no 
significant difference in mean tumour size between screen-
detected cancers and RCCs diagnosed in a hospital in the 
same region (incidental and symptomatic RCC detection), 
however, the authors postulate this may be secondary to the 
limited sample size and survival data were not reported. 
Malaeb et al. screened for RCC in asymptomatic veterans 
in conjunction with established AAA screening [50]. 80% 
survival was reported in patients with screen-detected RCC 
at 55-month follow-up. All the individuals who died were 
stage T3 at diagnosis. Taken together, these studies suggest 
there may be a potential survival benefit associated with 
early detection through screening for RCC. However, further 
evidence is required, utilising robust methodology (such as 
a randomised control trial with long-term follow-up data 
in a contemporary, well-defined population) to determine 
whether screening for RCC is associated with improved sur-
vival or whether there is simply a lead time bias.
Optimal screening population
One of the perceived barriers to population screening for 
RCC is the relatively low prevalence of the disease, with 
subsequent high cost to society to benefit only a small pro-
portion of individuals. A recent meta-analysis, pooling 
data from 11 studies on the prevalence of RCC detected by 
screening ultrasound, estimated that screening 1000 asymp-
tomatic individuals from the general population using ultra-
sound would allow the detection of between one and two 
cases of RCC [63]. Several high-risk groups exist, however.
Over 70% of patients with Von Hippel Lindau disease will 
develop RCC, often at an early age, and these individuals are 
also at high risk of adrenal and pancreatic tumours [7]. As 
such, annual surveillance with abdominal ultrasound and 
MRI is recommended to ensure early detection [64]. Patients 
with end-stage renal failure (ESRF) have an increased risk 
of RCC; 5–35 times higher than the general population [65, 
66]. This is secondary to the development of acquired cystic 
kidney disease (ACKD) and the risk is proportional to time 
on dialysis. There is insufficient evidence regarding whether 
screening for RCC in patients with ESRF is associated with 
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a survival benefit, due to the significantly reduced baseline 
life expectancy of this patient group [66–68]. Renal trans-
plant recipients are also at increased risk of RCC both in the 
native kidneys and in the graft; with rates of RCC 10–100 
times higher than the general population [69]. Due to struc-
tural differences within the kidneys of patients with ESRF 
and in renal transplant recipients, the sensitivity and speci-
ficity of ultrasound in these individuals remain uncertain, 
a major determinant of cost-effectiveness [65]. Contrast-
enhanced CT, especially in the corticomedullary phase, and 
non-contrast MRI have higher sensitivity and specificity than 
ultrasound in detecting and characterizing cystic lesions [70, 
71]. European Association of Urology guidelines published 
in 2005 and updated in 2009 recommended annual ultra-
sound screening of native kidneys and the graft in allograft 
recipients [69]. However, a subsequent Markov model simu-
lating annual and biennial screening suggested this is not a 
cost-effective strategy [65]. The Kidney Disease Improving 
Global Outcomes (KDIGO) and the American Society of 
Transplantation found insufficient evidence to recommend 
screening in renal transplant recipients [72], while the Kid-
ney Health Australia guideline recommends screening only 
in renal transplant recipients at high risk (past/family history 
of RCC or analgesic nephropathy; ungraded evidence) [73]. 
More research is necessary to clarify this.
It has been postulated that established risk factors for 
RCC may be used to identify individuals in the general popu-
lation who are at higher risk of the disease. Targeted screen-
ing of high-risk individuals may prove to be a cost-effective 
strategy by maximising benefits and reducing harms of 
screening [5, 50, 74]. For example, Starke et al. reported 
data on a group of 925 high-risk asymptomatic individuals 
identified as high risk based on age (≥ 50 years), smoking 
(≥ 10 pack-year smoking history) and occupational carcino-
gen exposure(≥ 15 years exposure). At 6.5-years follow-up, 
ten patients were diagnosed with RCC, giving a prevalence 
of 1.1% which is nearly ten times higher than in unselected 
groups representing the general population [75]. A national 
population registry including 12.2 million individuals also 
demonstrated an individual standardized incidence ratio of 
2.61 for RCC when a sibling is affected. Despite this famil-
ial clustering, there is insufficient evidence to recommend 
routine screening of individuals with one sibling affected 
with RCC [76]. Risk prediction models, incorporating fam-
ily history alongside other risk factors, may allow identifi-
cation of a high-risk group of individuals who may benefit 
from screening.
We, therefore, performed a systematic review to iden-
tify existing risk prediction models for the development of 
RCC. A similar approach has been adopted in other dis-
ease areas, including melanoma and colorectal cancer [77, 
78]. We reviewed 2973 article titles/abstracts. Our findings 
suggest there are no risk prediction models specific for the 
development of RCC at present. The only model identified 
was “Your Disease Risk” (https ://sitem an.wustl .edu/preve 
ntion /ydr/), which predicts the risk of 12 common cancers 
and six chronic diseases in the USA. However, this tool was 
created through expert consensus rather than patient-level 
data and its predictive ability and validity for renal cancer 
has not been established. The development of validated risk 
prediction models for RCC is, therefore, needed to explore 
the potential benefits of targeted screening; however, useful-
ness may be limited by the absence of risk factors specific to 
RCC, limiting specificity of the model. In future, it may be 
feasible to incorporate genomic as well as phenotypic fac-
tors in risk prediction models, to increase model accuracy.
Screening considerations: false positives 
and over‑diagnosis
Potential false negatives, false positives and over-diagnosis 
have been cited as barriers towards screening. The emo-
tional and psychological patient benefits and harms of RCC 
screening have yet to be quantified [63]. An evaluation of a 
screening programme for RCC must take into consideration 
the impact of incidentally detected benign renal lesions on 
patients and health services. At present, 15–30% of small 
renal masses (SRM) are found to be benign following sur-
gical excision [79–81]. Advances in the determination of 
the aetiology of SRMs, with increased utilization and bet-
ter interpretation of renal biopsy, may reduce these rates 
in future [82], as may novel urinary or serum biomarkers. 
Contrast-enhanced ultrasound (CEUS), an emerging imag-
ing modality, involves the injection of a microbubble con-
trast agent in addition to conventional ultrasound. Due to 
its invasive nature and requirements for trained staff it does 
not represent a candidate for screening. However, a meta-
analysis demonstrated a sensitivity of 88% and specificity 
of 80% in the differential diagnosis of benign and malig-
nant tumours, suggesting there may be a role for CEUS in 
complementing contrast abdominal CT for differentiation of 
benign and malignant renal masses in future [83].
Screening for RCC also raises the potential issue of 
over-diagnosis of slow-growing SRMs that would never 
become clinically significant [37]. Up to one-third of SRMs 
exhibit aggressive potential (rapid growth or doubling time 
< 12 months), with the remainder growing slowly or remain-
ing stable in size [84, 85]. Fenton et al. calculated that the 
sojourn time (mean duration of the detectable preclinical 
period) of RCC is between 3.7 and 5.8 years, suggesting 
that most RCs detected by CT screening among middle-aged 
Americans are likely to progress to clinical diagnosis [44]. 
Following advances in our understanding of the natural his-
tory of SRMs, active surveillance with delayed intervention, 
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either operative or ablative, has become a solution to reduce 
over-treatment.
Conclusion
RCC has a poor prognosis and incidence rates are rising, 
especially in the elderly population. Although screening for 
RCC remains an attractive prospect, the optimal screening 
modality and target population is yet to be determined. The 
development and validation of risk prediction models for 
RCC, containing phenotypic and genotypic data, is there-
fore, needed to explore the potential benefits of targeted 
screening. Urinary biomarkers constitute a promising future 
option as an inexpensive, readily accessible screening tool.
More research is required to assess whether screening 
translates to a survival benefit in the context of such a high 
number of incidentally detected lesions through the wide-
spread use of abdominal imaging. With ever-increasing 
demands on health services and a finite budget, it is para-
mount that a screening intervention is not only effective, 
but also cost effective. In the absence of randomized control 
trials, a value of information analysis conducted as part of a 
cost-effectiveness analysis based on existing data may high-
light areas to focus future research efforts. Most importantly, 
there is an ever-increasing focus on reducing harms associ-
ated with screening, and studies are required to quantify the 
emotional impact of RCC screening on patients, including 
anxiety and quality of life [12].
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